Mounjaro Price Increases, Explained

Eli Lilly, the manufacturer of Mounjaro, has increased the price of all dose strengths of Mounjaro in the UK to align prices across Europe. This means Wegovy is now a more cost-effective GLP-1 treatment for weight loss. We understand price increases are frustrating. At Pharmica, our priority is to help you continue your weight loss journey with as little disruption as possible, and to find the treatment that best supports your health goals and lifestyle.

If you are tolerating Mounjaro well and the new price is manageable, you can remain on your current plan. If you would like a more cost-effective alternative, Wegovy provides comparable weight loss results alongside added benefits such as reducing the risk of heart disease. Your safety is our main priority, and our clinicians will give you personalised guidance to keep your weight loss journey safe, effective and on track.

Yes. When switching from Mounjaro to Wegovy, you will be prescribed the starting Wegovy dose (0.25mg). This helps your body adjust gradually, minimises side effects and ensures the treatment remains safe and effective. Your dose will then be increased accordingly under clinical guidance from our experts to keep your progress on track.

Mounjaro currently shows greater average weight loss in clinical trials in the UK. It remains the most effective licensed option compared to Wegovy. However, Wegovy is still highly effective. At the maximum licensed dose of 2.4 mg, clinical studies show that individuals who used Wegovy can lose up to 17% of their body weight within 68 weeks. This is significantly more than most people achieve with other non-injectable weight loss medications or through lifestyle changes alone. A higher-strength dose of Wegovy (7.2mg) will become available toward the end of 2025. In clinical trials, patients lost an average of 21% of their starting body weight, with about one-third losing 25% of their starting weight or more. Side effects of this stronger dose were similar to the existing 2.4mg dose. Furthermore, compared to Mounjaro, Wegovy is approved in the UK for reducing the risk of heart disease, does not affect oral contraceptive efficacy, and is available at a lower cost than Mounjaro.

Wegovy and Mounjaro share many of the same side effects as they work in similar ways. If you tolerate Mounjaro well, you are less likely to experience new or worse effects when switching to Wegovy. Commonly experienced side effects from taking Wegovy include nausea, vomiting, constipation, diarrhoea, and stomach pain. Some people might also experience tiredness or headaches. These effects are generally mild and usually subside over time. These side effects can also be caused by dehydration or a lack of nutrient-rich foods in the diet.

Our clinically led team will guide you through the switch to ensure that Wegovy is safe and appropriate for you. You can contact us at any time for advice or if you have any questions about Wegovy. You also have access to our expert articles explaining how to get the most out of Wegovy. These include practical guidance, step-by-step injection videos, and tips on managing side effects.